Status:
UNKNOWN
CD133 Expression in Mammary Invasive Ductal Carcinoma
Lead Sponsor:
Sohag University
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
Background and Aim: Breast carcinoma is the most common type of cancer and the most common cause of cancer-related mortality among women worldwide. Cancer stem cells (CSCs) are thought to be responsib...
Detailed Description
Introduction: Breast carcinoma is the most frequent malignant tumor in women worldwide comprising 30% on average of all cancers and the most likely cause of cancer-related deaths in women worldwide. ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:• Inclusion criteria: Patients with IDC and underwent mastectomy or excisional biopsy of breast mass.
- \-
- Exclusion Criteria
- Patients received pre-operative chemotherapy or radiotherapy.
- Patients with insufficient clinical data.
Exclusion
Key Trial Info
Start Date :
May 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04873154
Start Date
May 1 2021
End Date
December 1 2021
Last Update
May 10 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Sohag University
Sohag, Egypt
2
Faculty of Medicine, Sohag University
Sohag, Egypt